Bispecific Antibody Deals Up 1800% in 2026 — Data

Nineteen bispecific antibody deals closed between February and August 2026, up from exactly one in the prior six-month window — an 1800% increase that represents the single largest modality-specific surge Ambrosia has tracked this year. This isn't a slow build. It's a phase transition. Big Pharma's bispecific appetite, dormant through most of 2025, has snapped into a feeding frenzy driven by clinical proof-of-concept data in solid tumors, competitive pressure from the ADC land grab, and genuine pipeline desperation among top-10 companies facing LOE cliffs between 2027 and 2030.

The Data — Bispecific Antibody Deal Activity, Period over Period

The contrast is stark. For the six months ending February 2026, bispecific antibody licensing activity was statistically dead — a single transaction in a modality that had generated significant academic and clinical interest but almost no transactional momentum. Then the dam broke. The current period's 19 deals span everything from early-stage platform access agreements to fully validated Phase 2 asset acquisitions with upfront payments exceeding $1 billion. To contextualize: Deal Benchmarks across all modalities show average period-over-period growth of roughly 15–25%. An 1800% jump is not a trend. It's a regime change.

What's Driving the Trend

Pipeline gaps are the primary accelerant. Pfizer, the most aggressive buyer in this cycle, faces approximately $17B in revenue at risk from LOE between 2027 and 2030 across its oncology and inflammation portfolios. Bispecifics — particularly T-cell engagers and checkpoint-by-checkpoint combinations — offer differentiated mechanisms that can't be easily replicated by biosimilar entrants. The calculus is straightforward: pay a premium now for assets with defensible IP and clinical differentiation, or compete in increasingly commoditized spaces later. Pfizer chose the former, twice, in the same week.

Clinical data inflected. Multiple bispecific programs reported pivotal or registration-enabling data in Q1 and Q2 2026, particularly in non-small cell lung cancer, hepatocellular carcinoma, and multiple myeloma. The historical knock on bispecifics — manageable but real cytokine release syndrome, narrow therapeutic windows, complex manufacturing — has been substantially addressed by next-generation formats. Step dosing protocols, subcutaneous delivery, and conditional activation technologies (see: CytomX's Probody platform) have materially improved the risk profile. Buyers noticed. When clinical and CMC risk simultaneously de-risk, deal velocity follows.

Competitive dynamics with ADCs created urgency. The ADC market absorbed over $40B in deal value through 2024 and 2025, and valuations stretched to levels many BD teams considered irrational. Bispecific antibody licensing in 2026 represents a pivot — buyers seeking next-generation oncology assets without paying ADC-peak multiples. The irony: the resulting demand surge is now pushing bispecific valuations toward the same territory. First movers like Pfizer locked in pricing before the market fully corrected. Latecomers will pay more.

Notable Deals

The Pfizer-3SBio transactions dominate the dataset. Two deals, six days apart, totaling $2.5B in upfront payments and $12.55B in combined total deal value. These are not options on early-stage science. These are conviction bets on clinical-stage bispecific assets with clear registration paths. The $1.3B upfront on the July 18 deal is the largest single upfront payment for a bispecific antibody licensing transaction on record. Pfizer is signaling that it views bispecifics as core to its post-LOE oncology strategy, not as a portfolio hedge. For benchmarking purposes, upfront-to-TDV ratios of 20% on these deals indicate high buyer confidence in milestone achievement — well above the historical modality average of 12–15%.

Jazz Pharmaceuticals' $4B TDV deal with AbCellera is notable for a different reason. AbCellera is primarily known as an antibody discovery platform, not an asset-stage company. A $4B TDV suggests Jazz is buying deep platform access — likely a multi-target, multi-format agreement that gives Jazz proprietary bispecific candidates across neuroscience or hematology. This is the kind of deal that mid-cap specialty pharma companies make when they want to build a pipeline in a single transaction rather than running five separate search-and-evaluate processes. Efficient, but concentrated risk.

The CytomX-Amgen collaboration is the sleeper. Two entries in the dataset a day apart suggest a restructured or expanded existing relationship — Amgen likely exercised an option or added targets under CytomX's Probody bispecific platform. The $40M upfront is modest, but Amgen's interest in conditionally activated bispecifics validates the thesis that next-generation safety engineering is a key differentiator. CytomX's masking technology directly addresses the therapeutic window concern that historically suppressed bispecific valuations.

What This Means for BD Teams Right Now

If you're selling bispecific assets, this is the best market in the modality's history. Upfront payments have shifted from 10–12% of TDV to 20%+ on marquee deals. Buyers are competing against each other on timelines, and the bid-ask spread has compressed. If you have Phase 1b or Phase 2 data in a solid tumor indication with a differentiated bispecific format, you should be running a competitive process now — not waiting for additional data readouts that marginally de-risk the asset but cost you negotiating leverage as more supply enters the market.

If you're buying, the window for reasonable pricing is closing. The Pfizer-3SBio deals have reset comp tables across the industry. Every banker and every biotech CEO with a bispecific program has those numbers in their model now. Pre-clinical platform deals — like the AbCellera-Jazz structure — may offer better value if you have internal development capabilities and the patience for longer timelines. Use Solidus to benchmark your term sheet against the current cycle's deal data before submitting an LOI.

Deal structures are shifting toward larger upfronts and fewer milestones. In a competitive environment, sellers are pushing for certainty — guaranteed payments over contingent ones. We're seeing fewer opt-in/opt-out structures and more outright licenses with development and commercial milestones front-loaded. Equity components, which gained traction in 2024–2025 when cash was tighter, are declining as a percentage of total consideration. Buyers with balance sheet firepower are using upfront cash as a competitive weapon. If you can't match Pfizer's $1.3B check, you need to compete on strategic value: co-development rights, geographic carve-outs, or platform extension terms.

Benchmark your deal against current market rates. The bispecific antibody market has repriced in real time, and comps from even six months ago are stale. Run your terms through the Ambrosia calculator to see where your structure sits relative to the 19 deals closed this cycle.